Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity - PubMed

• PMID: 3907840

Review

Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity

J S Steinberg et al. Clin Ther. 1985.

Abstract

Chemotherapy with doxorubicin often leads to congestive heart failure, particularly after cumulative doses of 550 mg/m2 have been reached. Certain risk factors, however, may predispose the patient to development of cardiomyopathy at lower doses. Radionuclide ventriculography with determinations of resting and exercise ejection fractions has emerged as the most reliable noninvasive screening procedure to detect subclinical cardiotoxicity. Before embarking on a course of doxorubicin therapy, patients should be stratified into low-risk and high-risk groups. Those in the high-risk group should undergo frequent monitoring by means of radionuclide ventriculography. For patients in the low-risk group, such monitoring could be postponed until they are ready to cross into the high-risk group by virtue of cumulative doxorubicin dose. Doxorubicin should be discontinued if the ejection fraction drops to less than or equal to 45% at rest or fails to increase with exercise.

Similar articles

• Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.

  Carrió I, Lopez-Pousa A, Estorch M, Duncker D, Berná L, Torres G, de Andrés L. Carrió I, et al. J Nucl Med. 1993 Sep;34(9):1503-7. J Nucl Med. 1993. PMID: 8355070

• Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.

  Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL. Alexander J, et al. N Engl J Med. 1979 Feb 8;300(6):278-83. doi: 10.1056/NEJM197902083000603. N Engl J Med. 1979. PMID: 759880

• Radionuclide ejection fraction in doxorubicin cardiotoxicity.

  Morgan GW, McIlveen BM, Freedman A, Murray IP. Morgan GW, et al. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):629-38. Cancer Treat Rep. 1981. PMID: 7248982

• Adriamycin (doxorubicin) cardiotoxicity: a review.

  Chlebowski RT. Chlebowski RT. West J Med. 1979 Nov;131(5):364-8. West J Med. 1979. PMID: 394479 Free PMC article. Review.

• Review of tests for monitoring doxorubicin-induced cardiomyopathy.

  Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Ganz WI, et al. Oncology. 1996 Nov-Dec;53(6):461-70. doi: 10.1159/000227621. Oncology. 1996. PMID: 8960141 Review.

Cited by

• Anthracyclines and the heart.

  Rhoden W, Hasleton P, Brooks N. Rhoden W, et al. Br Heart J. 1993 Dec;70(6):499-502. doi: 10.1136/hrt.70.6.499. Br Heart J. 1993. PMID: 8280512 Free PMC article. Review. No abstract available.

• A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

  Abraham R, Basser RL, Green MD. Abraham R, et al. Drug Saf. 1996 Dec;15(6):406-29. doi: 10.2165/00002018-199615060-00005. Drug Saf. 1996. PMID: 8968695 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information